



JALBCA

JUDGES AND LAWYERS
BREAST CANCER ALERT

Vol. 19 No. 1

Editor: Martha L. Golar, Esq.

March 2014

SAVE THE DATE

JALBCA ANNUAL DINNER

DATE: Monday, May 12, 2014
PLACE: Cipriani Wall Street, Manhattan
TIME: Silent Auction/ 6 pm Cocktails/ 7 pm Dinner
HONORING: Hon. Jonathan Lippman
Chief Judge of the New York Court of Appeals
and
Jill A. Centella and the
JP Morgan Chase & Co. Litigation Team

INCOMING JALBCA OFFICERS

At its annual dinner, JALBCA will install and welcome its new officers for the 2014-2015 year, as listed below. The newly elected members of the JALBCA Board and Advisory Board will also be installed.

Presidents

Hon. Lynn Kotler Sharon L. Nelles, Esq.

Vice Presidents

Jacqueline Flug, Esq. Vilia B. Hayes, Esq.

Hon. Lori Sattler Hon. Lisa Sokoloff

Secretary

Hon. Saliann Scarpulla

Treasurer

Hon. William C. Thompson

Assistant Secretary

Sandra Lespinasse, Esq.

Assistant Treasurers

Sandra C. Katz, Esq.

Edward S. Kornreich, Esq.

SAVE THE DATE

The Ellen Hermanson Foundation

Summer Solstice

Saturday, June 21, 2014

Southampton, NY

For additional information, contact info@ellensrun.org

212.840.0916

JALBCA 2014 COURTHOUSE ALERT SCHEDULE

JALBCA has its preliminary schedule for mammography vans in the metropolitan area. The mobile mammography units are provided by Project Renewal, which arranges for the van's medical team. Please refer to the schedule below and contact a JALBCA Coordinator if you are able to assist in posting announcements for the relevant location. Mammograms would be provided free of charge for women 40 and older who have not had a mammogram in the past year.

DATE	LOCATION	DATE	LOCATION
February 16	Margarita's Breast Support Group, Bronx	October 7	Suffolk County Family Court
March 8	Women's Shelter, Manhattan	October 9	NYC Civil Court
March 29	Louis H Pink Community Center	October 16	NYC Civil Court SI
April 1	Riverdale YWHA	October 20	Kings County Supreme Court
April 3	Amalgamated Houses, 74 Van Courtland Park So	October 22	Richmond County Supreme Court
April 5	Staten Island Mall	October 24	Queens Family Court
April 6	Twistomi Association	October 28	Bronx Family Court
April 7	Helen B Atkinson Health Center	October 30	Queens Supreme Court (LIC)
April 11	Community League of 159th St.	October 31	Harlem Community Justice Center
April 25	Greenpoint Library (Leonard & Norman Aves.)	November 10	Brooklyn Family Court (Jay St.)
April 2	Baychester Library (Co-Op City)	November 24	Richmond County Supreme Court
May 6	Red Hook Public Library		
May 7	Brooklyn Adult Learning Ctr., 475 Nostrand Ave.		JALBCA Coordinators for the Courthouse Alert in New York City boroughs are as follows: Jacqueline Flug: Manhattan/Bronx; EJ Thorsen: Queens; Janessa Trotto: Suffolk County; Hon. Ellen Spodek: Brooklyn.
May 13	Callen-Lorde Health Center		
August 28	Riverhead Criminal Court Buildings		
October 3	Bronx Supreme Court		

JALBCA LUNCH & LEARN PROGRAM

On March 6, 2014, the New York County Supreme Court and JALBCA presented a program on breast cancer awareness and early detection. More than 30 guests, including court staff, clerks and employees of the DCAS, attended this informative event featuring Mary Solomon, Director of the Scan Van Mobile Mammography Van Program. The feedback from the guests was tremendous as attendees learned life-saving information about breast cancer awareness. The program was coordinated by Hon. Lynn Kotler.

The Hofstra Law Women and Health Law Society of Hofstra University School of Law sponsored a similar program on March 12, 2014. Mary Solomon shared eye-opening facts and helpful tips on early detection, and the audience was introduced to JALBCA and its programs, including the breast cancer hotline. The event, which took place on the campus, welcomed Hofstra law students, faculty and administrators. The student guests, in particular, remarked that the presentation inspired them to become ambassadors in breast cancer education.

On April 17, 2014, Mary Solomon will be speaking at the Civil Court in Queens County at a program sponsored by the Queens County Women's Bar Association in association with JALBCA.



left to right: Arielle Albert, Esq.; EJ Thorsen, Esq.; Hofstra Law students Kelsey Walker and Aileen Iorio; Mary Solomon; and Hofstra Law Director of Career and Professional Development, Aisha Joseph, Esq.

NEWS BRIEFS

Patients' Rights to Their Laboratory Test Reports

The U.S. Department of Health and Human Services recently published a Final Rule which grants to patients and their personal representatives access to the patient's completed laboratory test reports directly from the lab maintaining the information. This provides patients a means to obtain their lab results, without requesting them. The goal of the Final Rule is to provide individuals with a greater ability to access their

health information, empowering them to take a more active role in managing their health care. Laboratories will not be required to interpret test results for an individual and may refer an individual back to his or her provider if they receive such requests for interpretation.

The Final Rule was published jointly by the Office for Civil Rights, the Centers for Medicare & Medicaid Services and the Centers for Disease Control. It amends the Clinical Laboratory Improvement Amend-

ments of 1988 (CLIA) and the Health Insurance Portability and Accountability Act of 1996 (HIPAA). By October 6, 2014, laboratories qualifying as covered entities under HIPAA must comply with an individual's request for access to certain protected health information, including laboratory test results concerning that individual that are part of the laboratory's designated record set. The Final Rule also amends CLIA regulations to specify that, upon the request of a patient (or the patient's person-

al representative), laboratories subject to CLIA may provide the patient, the patient's personal representative, or a person designated by the patient, as applicable, with copies of completed test reports that, using the laboratory's authentication process, can be identified as belonging to that patient. Also, these expanded access rules preempt contrary state law prohibiting the release of lab test information without the ordering provider's consent under HIPAA's preemption regulations.

Cancer Biomarkers

In cancer research and medicine, biomarkers are used primarily for diagnostic, prognostic and predictive purposes. Diagnostically, biomarkers are used to help identify early stage cancers; prognostically, biomarkers are used to forecast how aggressive a condition is. Predictively, biomarkers are used to determine how well a patient will respond to treatment. Biomarkers are not precise predictors of health or disease, or response to treatment, but it is hoped physicians could use them to personalize treatment for individual patients thereby improving the treatment's effectiveness and safety. Some potentially promising biomarkers relevant to breast cancer are described below.

The PI3K/AKT/mTor Pathway

Phosphatidylinositol 3-kinase (PI3K) is thought to play an important role in the formation of tumors. The PI3K signaling pathway – the PI3K/AKT/mTOR pathway – is said to regulate many critical aspects of normal and cancer physiology, e.g., cell proliferation, apoptosis, cell morphology and

migration, protein synthesis, and integration of metabolism. Inhibitors targeting this pathway are actively under study. In breast cancer, mutations that activate this pathway occur in many tumors. Improved understanding of the biologic consequence of altered PI3K/AKT/mTOR signaling is being used to develop protein and genetic biomarkers that would identify patients most likely to benefit from this therapeutic strategy. Everolimus is one example of an allosteric mTor inhibitor. In July 2012, the FDA approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The drug combination is intended for use in women with recurrence or progression of their cancer after treatment with Femara (letrozole) or Arimidex (anastrozole). Everolimus (previously approved for advanced renal cancer) is the first mTOR inhibitor approved by the FDA for this indication.

The CYP2D6-Tamoxifen Relationship

CYP2D6 is a member of the cytochrome P450 family of enzymes involved in the oxidative metabolism of drugs. There are inconsistent research results on whether the inherited variation of the gene cytochrome P450 2D6 (CYP2D6) and the use of CYP2D6-inhibiting medications can negatively affect overall survival in patients with metastatic breast cancer. It is known that CYP2D6 is necessary to metabolize tamoxifen. Tamoxifen is thereby converted into the active metabolite endoxifen. Some studies have concluded that patients with reduced CYP2D6 activity, as a result of

either the genotype or induction by the co-administration of drugs that inhibit CYP2D6 function, produce little endoxifen and experience less therapeutic benefit from tamoxifen. A further possible conclusion, then, is that the use of drugs that inhibit CYP2D6 would worsen the outcome of tamoxifen therapy. (<http://www.ncbi.nlm.nih.gov/pubmed/23760858>) One class of drugs that inhibit CYP2D6 is the selective serotonin reuptake inhibitors – SSRIs (e.g., paroxetine, fluoxetine) – which are typically used in the treatment of depression. However, other host and tumor factors, besides CYP2D6, contribute to tamoxifen response/resistance. (<http://jco.ascopubs.org/content/31/2/176>)

Trim62

A protein known as Trim62 could be a potential biomarker to predict the biologic response of breast cancer cells to anti-HER2 therapeutics such as lapatinib (Tykerb), a HER2/epidermal growth-factor receptor inhibitor. Investigators have found that Trim62 regulates the stability and location of p27 in tumor cells. P27 is a cell-cycle inhibitory protein that is thought to be predictive of a poor outcome in breast cancers, which is a very simplified description of its role. P27 is over-expressed in HER2-positive breast cancers. (<http://www.medscape.com/viewarticle/712905>, from the AACR-NCI-EORTC 2009 International Conference on Molecular Targets and Cancer Therapeutics.)

NOTE: This Newsletter is reporting on scientific research and takes no position with respect to researchers' conclusions derived from such studies.

SAVE THE DATE — NYU CANCER INSTITUTE CANCER EDUCATION SERIES

Members may be interested in some of the many upcoming community talks, screenings and programs offered by the NYU Cancer Institute. See March and April programs of note:

- March 19** Cancer Survivorship Lecture Series: Following Diet and Exercise Guidelines Along the Cancer Journey – 5:30-6:30 pm
- March 20** What EveryBODY Needs to Know About Cancer: Key Issues for Lesbians, Bisexual Women and Transgender People – 6:00-7:30 pm
- March 26** Update from the 36th Annual San Antonio Breast Cancer Symposium – 6:00 pm
- March 27** Prostate Cancer Education Series: Nutrition Health for Prostate Cancer Survivors – 5:30-6:30 pm
- April 8** Update on Progress in Metastatic Breast Cancer 6:00 - 8:00 pm. Bellevue Hospital Center, Saul Farber Auditorium (program in collaboration with Bellevue Hospital Cancer Center and SHARE)
- April 10** The Affordable Health Care Act: How to Prepare for Changes in Your Coverage – 6:00-7:30 pm

The lectures will take place at the NYU Langone Medical Center, NY, NY, unless specified otherwise. For additional information and future postings, please visit www.NYUCL.org. To RSVP, which is required, please call 212.263.2266 or e-mail NYUCIcommunityprograms@NYUMC.org. You may also reserve online. Prior programs are available for viewing on the medical center's YouTube channel at YouTube.com/nyulmc.

JALBCA

c/o Jennifer Fiorentino
Executive Director
1324 Lexington Avenue, PMB 324
New York, New York 10128
www.jalbca.org

Address Service Requested



CALENDAR/CONTACTS

ADELPHI NY STATEWIDE BREAST CANCER

Hotline & Support Program
Adelphi University School of Social Work
Garden City, NY 11530
www.breastcancerhotline@adelphi.edu

CancerCare

275 Seventh Avenue
New York, NY 10001
www.cancercare.org
1.800.813.HOPE (4673)

ELLEN'S RUN

200 West End Avenue, Suite 12 G
New York, NY 10023
www.ellensrun.org
212.840.0916

MEMORIAL SLOAN KETTERING CANCER CENTER

Post-Treatment Resource Program
Educational Forums
215 E. 68th St., Ground Fl.
New York, NY 10021
www.mskcc.org
212.717.3527

Bendheim Integrative Medicine Center

1429 First Avenue (at 74th Street)
New York, NY

SHARE (*Self-Help for Women with Breast or Ovarian Cancer*)

1501 Broadway, Ste. 704A
New York, NY
www.sharecancersupport.org
212.719.0364
Speak to a survivor toll-free:
1.866.891.2392

TO LIFE!

410 Kenwood Avenue
Delmar, NY 12054
518.439.5975
110 Spring Street
Saratoga Springs, NY 12866
518.587.3820
www.tolife.org

YOUNG SURVIVAL COALITION

61 Broadway
New York, NY
www.youngsurvival.org
646.257.3025